

Jan Koster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2821436/publications.pdf>

Version: 2024-02-01

204
papers

25,865
citations

18436

62
h-index

7136

153
g-index

219
all docs

219
docs citations

219
times ranked

34024
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients. <i>Cell</i> , 2015, 161, 933-945.	13.5	1,710
2	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	7.7	1,551
3	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	13.7	1,068
4	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	7.7	933
5	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. <i>Acta Neuropathologica</i> , 2012, 123, 473-484.	3.9	863
6	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	13.7	787
7	Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. <i>Nature</i> , 2012, 483, 589-593.	13.7	775
8	Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , 2012, 488, 100-105.	13.7	765
9	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. <i>Cell</i> , 2012, 148, 59-71.	13.5	743
10	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	13.5	702
11	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. <i>Cancer Cell</i> , 2015, 28, 666-676.	7.7	700
12	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. <i>Nature Genetics</i> , 2013, 45, 927-932.	9.4	674
13	The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent α^4 cell markers. <i>EMBO Journal</i> , 2012, 31, 3079-3091.	3.5	634
14	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	7.7	627
15	Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features. <i>PLoS ONE</i> , 2008, 3, e3088.	1.1	606
16	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014, 506, 445-450.	13.7	521
17	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	13.7	520
18	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. <i>Nature Genetics</i> , 2015, 47, 864-871.	9.4	451

#	ARTICLE	IF	CITATIONS
19	Differentiated Troy ⁺ Chief Cells Act as Reserve Stem Cells to Generate All Lineages of the Stomach Epithelium. <i>Cell</i> , 2013, 155, 357-368.	13.5	445
20	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	7.7	438
21	Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy. <i>Cancer Research</i> , 2009, 69, 2065-2071.	0.4	405
22	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. <i>Nature</i> , 2014, 510, 537-541.	13.7	378
23	Clonal selection drives genetic divergence of metastatic medulloblastoma. <i>Nature</i> , 2012, 482, 529-533.	13.7	376
24	Neuroblastoma is composed of two super-enhancer-associated differentiation states. <i>Nature Genetics</i> , 2017, 49, 1261-1266.	9.4	362
25	LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. <i>Nature Genetics</i> , 2012, 44, 1199-1206.	9.4	336
26	TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. <i>Nature Genetics</i> , 2015, 47, 1411-1414.	9.4	313
27	Methylation of Cancer-Stem-Cell-Associated Wnt Target Genes Predicts Poor Prognosis in Colorectal Cancer Patients. <i>Cell Stem Cell</i> , 2011, 9, 476-485.	5.2	291
28	Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors. <i>Cancer Cell</i> , 2015, 27, 298-311.	7.7	248
29	Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19190-19195.	3.3	215
30	Genome-Wide Pattern of TCF7L2/TCF4 Chromatin Occupancy in Colorectal Cancer Cells. <i>Molecular and Cellular Biology</i> , 2008, 28, 2732-2744.	1.1	208
31	Analysis of the interactions between BP180, BP230, plectin and the integrin $\alpha 6 \beta 4$ important for hemidesmosome assembly. <i>Journal of Cell Science</i> , 2003, 116, 387-399.	1.2	206
32	NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome. <i>Cell</i> , 2010, 142, 218-229.	13.5	190
33	The Three-Dimensional Structure of Human Interphase Chromosomes Is Related to the Transcriptome Map. <i>Molecular and Cellular Biology</i> , 2007, 27, 4475-4487.	1.1	151
34	SIRT1/PGC1 α -Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2870-2879.	3.2	151
35	Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12968-12973.	3.3	147
36	c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies. <i>Nature Immunology</i> , 2019, 20, 992-1003.	7.0	142

#	ARTICLE	IF	CITATIONS
37	Cyclin D1 and CDK4 Activity Contribute to the Undifferentiated Phenotype in Neuroblastoma. <i>Cancer Research</i> , 2008, 68, 2599-2609.	0.4	141
38	ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma Outcome. <i>Cancer Cell</i> , 2009, 15, 328-340.	7.7	132
39	Domain-wide regulation of gene expression in the human genome. <i>Genome Research</i> , 2007, 17, 1286-1295.	2.4	127
40	FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma. <i>Cancer Research</i> , 2013, 73, 2189-2198.	0.4	124
41	A biobank of patient-derived pediatric brain tumor models. <i>Nature Medicine</i> , 2018, 24, 1752-1761.	15.2	124
42	Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. <i>Cancer Discovery</i> , 2018, 8, 582-599.	7.7	119
43	Role of Binding of Plectin to the Integrin $\alpha 24$ Subunit in the Assembly of Hemidesmosomes. <i>Molecular Biology of the Cell</i> , 2004, 15, 1211-1223.	0.9	115
44	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). <i>Acta Neuropathologica</i> , 2012, 124, 875-881.	3.9	115
45	A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. <i>Nature Communications</i> , 2019, 10, 1530.	5.8	108
46	Apc-mutant cells act as supercompetitors in intestinal tumour initiation. <i>Nature</i> , 2021, 594, 436-441.	13.7	108
47	Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 455-467.	1.5	98
48	The molecular landscape of ETMR at diagnosis and relapse. <i>Nature</i> , 2019, 576, 274-280.	13.7	94
49	Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. <i>Endocrine-Related Cancer</i> , 2011, 18, 657-668.	1.6	89
50	Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion. <i>Oncogene</i> , 2016, 35, 5263-5271.	2.6	87
51	FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF- κ B to promote survival of human B cells. <i>Blood</i> , 2014, 124, 3431-3440.	0.6	86
52	Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. <i>Oncogene</i> , 2013, 32, 2927-2936.	2.6	84
53	Mutations in the Ras-Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3132-3141.	3.2	79
54	Extensive Polycistronism and Antisense Transcription in the Mammalian Hox Clusters. <i>PLoS ONE</i> , 2007, 2, e356.	1.1	78

#	ARTICLE	IF	CITATIONS
55	PDGFRB Promotes Liver Metastasis Formation of Mesenchymal-Like Colorectal Tumor Cells. <i>Neoplasia</i> , 2013, 15, 204-IN30.	2.3	78
56	A novel gene expression signature for bone metastasis in breast carcinomas. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 249-259.	1.1	77
57	GPx2 Suppression of H2O2 Stress Links the Formation of Differentiated Tumor Mass to Metastatic Capacity in Colorectal Cancer. <i>Cancer Research</i> , 2014, 74, 6717-6730.	0.4	76
58	Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase. <i>Nature</i> , 2019, 567, 545-549.	13.7	76
59	The RNA Atlas expands the catalog of human non-coding RNAs. <i>Nature Biotechnology</i> , 2021, 39, 1453-1465.	9.4	75
60	OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells. <i>International Journal of Cancer</i> , 2012, 131, E21-32.	2.3	74
61	Colonic CD90+ Crypt Fibroblasts Secrete Semaphorins to Support Epithelial Growth. <i>Cell Reports</i> , 2019, 26, 3698-3708.e5.	2.9	74
62	The Hemidesmosomal Protein Bullous Pemphigoid Antigen 1 and the Integrin $\alpha 24$ Subunit Bind to ERBIN. <i>Journal of Biological Chemistry</i> , 2001, 276, 32427-32436.	1.6	73
63	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1084-1093.	3.0	73
64	Super enhancers define regulatory subtypes and cell identity in neuroblastoma. <i>Nature Cancer</i> , 2021, 2, 114-128.	5.7	73
65	Prevalence and clinical implications of chromothripsis in cancer genomes. <i>Current Opinion in Oncology</i> , 2014, 26, 64-72.	1.1	71
66	The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta ϵ Notch pathway in neuroblastoma. <i>Experimental Cell Research</i> , 2008, 314, 707-719.	1.2	70
67	Hypermutation of the Inactive X Chromosome Is a Frequent Event in Cancer. <i>Cell</i> , 2013, 155, 567-581.	13.5	67
68	In search of druggable targets for GBM amino acid metabolism. <i>BMC Cancer</i> , 2017, 17, 162.	1.1	67
69	The Role of Histone Demethylase KDM4B in Myc Signaling in Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv080.	3.0	63
70	Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. <i>Oncogene</i> , 2009, 28, 2015-2023.	2.6	61
71	Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. <i>European Journal of Cancer</i> , 2012, 48, 763-771.	1.3	61
72	The interaction of plectin with actin: evidence for cross-linking of actin filaments by dimerization of the actin-binding domain of plectin. <i>Journal of Cell Science</i> , 2001, 114, 2065-2076.	1.2	59

#	ARTICLE	IF	CITATIONS
73	Prevalence and Patterns of Morphological Abnormalities in Patients With Childhood Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 61-9.	3.8	57
74	Copy number defects of G1 cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 10-19.	1.5	57
75	Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. <i>European Journal of Cancer</i> , 2014, 50, 628-637.	1.3	57
76	A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities. <i>Nature Communications</i> , 2020, 11, 2935.	5.8	57
77	Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. <i>Oncogene</i> , 2012, 31, 1571-1581.	2.6	55
78	Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor suppressor. <i>International Journal of Cancer</i> , 2018, 143, 2828-2837.	2.3	54
79	The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. <i>International Journal of Cancer</i> , 2010, 126, 2012-2024.	2.3	52
80	Driver mutations of the adenoma-carcinoma sequence govern the intestinal epithelial global translational capacity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25560-25570.	3.3	50
81	Charting Extracellular Transcriptomes in The Human Biofluid RNA Atlas. <i>Cell Reports</i> , 2020, 33, 108552.	2.9	50
82	Two Different Mutations in the Cytoplasmic Domain of the Integrin $\beta 4$ Subunit in Nonlethal Forms of Epidermolysis Bullosa Prevent Interaction of $\beta 4$ with Plectin. <i>Journal of Investigative Dermatology</i> , 2001, 117, 1405-1411.	0.3	49
83	High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. <i>Oncotarget</i> , 2016, 7, 27946-27958.	0.8	47
84	Specificity of Binding of the Plectin Actin-binding Domain to $\beta 4$ Integrin. <i>Molecular Biology of the Cell</i> , 2003, 14, 4039-4050.	0.9	46
85	Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome. <i>Cancer Cell</i> , 2016, 30, 548-562.	7.7	46
86	Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. <i>Nature Communications</i> , 2021, 12, 1269.	5.8	46
87	The PDZ domain of TIP-2/GIPC interacts with the C-terminus of the integrin $\beta 5$ and $\beta 6$ subunits. <i>Matrix Biology</i> , 2002, 21, 207-214.	1.5	45
88	Regulation of Cell Cycle Genes and Induction of Senescence by Overexpression of OTX2 in Medulloblastoma Cell Lines. <i>Molecular Cancer Research</i> , 2010, 8, 1344-1357.	1.5	45
89	DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. <i>International Journal of Oncology</i> , 2013, 42, 1219-1228.	1.4	45
90	Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment development. <i>Oncogene</i> , 2018, 37, 5694-5700.	2.6	45

#	ARTICLE	IF	CITATIONS
91	A NOTCH3 Transcriptional Module Induces Cell Motility in Neuroblastoma. <i>Clinical Cancer Research</i> , 2013, 19, 3485-3494.	3.2	44
92	Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 3319-3332.	3.2	44
93	Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. <i>European Journal of Cancer</i> , 2012, 48, 3093-3103.	1.3	43
94	RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma. <i>Cancer Research</i> , 2018, 78, 6297-6307.	0.4	43
95	Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation. <i>Cancer Letters</i> , 2007, 256, 218-228.	3.2	42
96	OTX2 sustains a bivalent-like state of OTX2-bound promoters in medulloblastoma by maintaining their H3K27me3 levels. <i>Acta Neuropathologica</i> , 2013, 125, 385-394.	3.9	42
97	Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. <i>European Journal of Cancer</i> , 2007, 43, 2413-2422.	1.3	41
98	MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3. <i>Cancer Letters</i> , 2010, 289, 195-207.	3.2	40
99	Discovery and visualization of miRNA-mRNA functional modules within integrated data using bicluster analysis. <i>Nucleic Acids Research</i> , 2014, 42, e17-e17.	6.5	40
100	Patient-Derived Xenograft Models Reveal Intratumor Heterogeneity and Temporal Stability in Neuroblastoma. <i>Cancer Research</i> , 2018, 78, 5958-5969.	0.4	40
101	Efficient Double Fragmentation ChIP-seq Provides Nucleotide Resolution Protein-DNA Binding Profiles. <i>PLoS ONE</i> , 2010, 5, e15092.	1.1	39
102	Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. <i>International Journal of Cancer</i> , 2011, 128, 2296-2305.	2.3	38
103	Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. <i>British Journal of Cancer</i> , 2012, 107, 1399-1408.	2.9	38
104	Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma. <i>Biochemical Journal</i> , 2018, 475, 531-545.	1.7	37
105	Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 649-659.	1.1	37
106	Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways. <i>Science Signaling</i> , 2018, 11, .	1.6	36
107	Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. <i>Oncogene</i> , 2010, 29, 2739-2745.	2.6	35
108	ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of <i>ALK</i> mutation. <i>EMBO Journal</i> , 2021, 40, e105784.	3.5	35

#	ARTICLE	IF	CITATIONS
109	<i>CDK2</i> expression is a marker for neuroblastic tumor maturation and is downregulated by MYCN. <i>International Journal of Cancer</i> , 2008, 122, 1455-1464.	2.3	34
110	Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells. <i>Endocrine-Related Cancer</i> , 2010, 17, 399-414.	1.6	33
111	Maintenance of Clonogenic KIT+ Human Colon Tumor Cells Requires Secretion of Stem Cell Factor by Differentiated Tumor Cells. <i>Gastroenterology</i> , 2015, 149, 692-704.	0.6	32
112	Eomes broadens the scope of CD8 T-cell memory by inhibiting apoptosis in cells of low affinity. <i>PLoS Biology</i> , 2020, 18, e3000648.	2.6	31
113	Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. <i>PLoS ONE</i> , 2016, 11, e0166233.	1.1	31
114	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 5645-5657.	3.2	30
115	MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma. <i>Oncotarget</i> , 2016, 7, 66344-66359.	0.8	30
116	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-11.	2.5	28
117	MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma. <i>Oncotarget</i> , 2018, 9, 20323-20338.	0.8	28
118	Meta-mining of copy number profiles of high-risk neuroblastoma tumors. <i>Scientific Data</i> , 2018, 5, 180240.	2.4	27
119	Read-through transcript from NM23-H1 into the neighboring NM23-H2 gene encodes a novel protein, NM23-LV. <i>Genomics</i> , 2006, 87, 483-489.	1.3	26
120	Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies. <i>Experimental Cell Research</i> , 2017, 360, 397-403.	1.2	26
121	Ataxia-telangiectasia mutated (<i>ATM</i>) silencing promotes neuroblastoma progression through a <i>MYCN</i> independent mechanism. <i>Oncotarget</i> , 2015, 6, 18558-18576.	0.8	26
122	Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. <i>BMC Cancer</i> , 2012, 12, 285.	1.1	25
123	snoRNPs Regulate Telomerase Activity in Neuroblastoma and Are Associated with Poor Prognosis. <i>Translational Oncology</i> , 2013, 6, 447-456.	1.7	25
124	Joint Binding of OTX2 and MYC in Promotor Regions Is Associated with High Gene Expression in Medulloblastoma. <i>PLoS ONE</i> , 2011, 6, e26058.	1.1	24
125	Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. <i>Molecular Carcinogenesis</i> , 2011, 50, 403-411.	1.3	24
126	Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. <i>British Journal of Cancer</i> , 2012, 107, 1409-1417.	2.9	24

#	ARTICLE	IF	CITATIONS
127	Novel Interaction of Ornithine Decarboxylase with Sepiapterin Reductase Regulates Neuroblastoma Cell Proliferation. <i>Journal of Molecular Biology</i> , 2014, 426, 332-346.	2.0	24
128	Indian Hedgehog Suppresses a Stromal Cell-Driven Intestinal Immune Response. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 67-82.e1.	2.3	24
129	Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity. <i>British Journal of Cancer</i> , 2022, 126, 1824-1833.	2.9	24
130	Expression of Prenylated Rab Acceptor 1 Domain Family, Member 2 (PRAF2) in Neuroblastoma: Correlation with Clinical Features, Cellular Localization, and Cerulenin-Mediated Apoptosis Regulation. <i>Clinical Cancer Research</i> , 2007, 13, 6312-6319.	3.2	23
131	The TRPM7 interactome defines a cytoskeletal complex linked to neuroblastoma progression. <i>European Journal of Cell Biology</i> , 2016, 95, 465-474.	1.6	23
132	Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. <i>European Journal of Cancer</i> , 2017, 75, 63-72.	1.3	23
133	Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. <i>EBioMedicine</i> , 2019, 50, 81-92.	2.7	23
134	A Novel Organoid Model of Damage and Repair Identifies HNF4 α as a Critical Regulator of Intestinal Epithelial Regeneration. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 209-223.	2.3	23
135	CD44 Expression in Intestinal Epithelium and Colorectal Cancer Is Independent of p53 Status. <i>PLoS ONE</i> , 2013, 8, e72849.	1.1	23
136	Molecular Consequences of Deletion of the Cytoplasmic Domain of Bullous Pemphigoid 180 in a Patient with Predominant Features of Epidermolysis Bullosa Simplex. <i>Journal of Investigative Dermatology</i> , 2004, 122, 65-72.	0.3	22
137	Deoxyhypusine synthase (DHPS) inhibitor GC7 induces p21/Rb-mediated inhibition of tumor cell growth and DHPS expression correlates with poor prognosis in neuroblastoma patients. <i>Cellular Oncology (Dordrecht)</i> , 2014, 37, 387-398.	2.1	22
138	DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells. <i>PLoS ONE</i> , 2015, 10, e0145744.	1.1	22
139	Subcellular distribution and expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in malignant glioma: Influence on cell survival and migration. <i>Cancer Science</i> , 2010, 101, 1624-1631.	1.7	21
140	A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients. <i>Scientific Reports</i> , 2019, 9, 6577.	1.6	21
141	MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 58-69.	0.6	21
142	Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28061.	0.8	21
143	Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target. <i>BMC Cancer</i> , 2015, 15, 477.	1.1	20
144	PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. <i>International Journal of Cancer</i> , 2012, 131, 1556-1568.	2.3	19

#	ARTICLE	IF	CITATIONS
145	Whole-Genome Sequencing Identifies Patient-Specific DNA Minimal Residual Disease Markers in Neuroblastoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 43-52.	1.2	19
146	Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma. <i>Oncotarget</i> , 2016, 7, 63629-63639.	0.8	19
147	Interferon-induced epithelial response to rhinovirus 16 in asthma relates to inflammation and FEV1. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 442-447.e10.	1.5	18
148	Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene. <i>Carcinogenesis</i> , 2020, 41, 284-295.	1.3	18
149	Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors. <i>Cancer Research</i> , 2022, 82, 484-496.	0.4	18
150	Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients. <i>Carcinogenesis</i> , 2017, 38, 1011-1020.	1.3	17
151	Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	17
152	Early Life Antibiotics Influence In Vivo and In Vitro Mouse Intestinal Epithelium Maturation and Functioning. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 943-981.	2.3	17
153	Macrophages induce "budding" in aggressive human colon cancer subtypes by protease-mediated disruption of tight junctions. <i>Oncotarget</i> , 2018, 9, 19490-19507.	0.8	17
154	Antipeptin autoantibodies in subepidermal blistering diseases. <i>British Journal of Dermatology</i> , 2009, 161, 762-771.	1.4	16
155	Defects in 8-oxo-guanine repair pathway cause high frequency of C & G A substitutions in neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	16
156	Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging. <i>British Journal of Cancer</i> , 2022, 127, 145-155.	2.9	16
157	The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells <i>in vivo</i> . <i>International Journal of Cancer</i> , 2009, 124, 2488-2494.	2.3	15
158	PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma. <i>International Journal of Oncology</i> , 2013, 42, 1408-1416.	1.4	15
159	Hey1- and p53-dependent TrkC proapoptotic activity controls neuroblastoma growth. <i>PLoS Biology</i> , 2018, 16, e2002912.	2.6	14
160	Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients. <i>Scientific Reports</i> , 2021, 11, 5307.	1.6	14
161	SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells. <i>Scientific Reports</i> , 2016, 6, 31615.	1.6	13
162	Specific and Sensitive Detection of Neuroblastoma mRNA Markers by Multiplex RT-qPCR. <i>Cancers</i> , 2021, 13, 150.	1.7	13

#	ARTICLE	IF	CITATIONS
163	Abstract A2-45: R2: Accessible web-based genomics analysis and visualization platform for biomedical researchers. <i>Cancer Research</i> , 2015, 75, A2-45-A2-45.	0.4	13
164	Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight. <i>Cell Reports Medicine</i> , 2021, 2, 100472.	3.3	13
165	Tumors Widely Express Hundreds of Embryonic Germline Genes. <i>Cancers</i> , 2020, 12, 3812.	1.7	12
166	A secondary role for hypoxia and HIF1 in the regulation of (IFN γ -induced) PD-L1 expression in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 529-540.	2.0	12
167	Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer. <i>BMC Cancer</i> , 2017, 17, 755.	1.1	11
168	Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma. <i>Cancer Research</i> , 2018, 78, 1935-1947.	0.4	11
169	Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies. <i>European Journal of Cancer</i> , 2022, 162, 107-117.	1.3	11
170	AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma. <i>IScience</i> , 2022, 25, 104398.	1.9	10
171	Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use. <i>International Journal of Cancer</i> , 2015, 137, 868-877.	2.3	9
172	Maternal diabetes causes developmental delay and death in early-somite mouse embryos. <i>Scientific Reports</i> , 2017, 7, 11714.	1.6	9
173	Calcium signaling regulates fundamental processes involved in Neuroblastoma progression. <i>Cell Calcium</i> , 2019, 82, 102052.	1.1	8
174	Mutational spectrum of <i>ATR</i> aberrations in neuroblastoma and associated patient and tumor characteristics. <i>Cancer Science</i> , 2022, 113, 2167-2178.	1.7	8
175	Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers. <i>European Journal of Cancer</i> , 2020, 130, 168-181.	1.3	7
176	Robust Selection of Cancer Survival Signatures from High-Throughput Genomic Data Using Two-Fold Subsampling. <i>PLoS ONE</i> , 2014, 9, e108818.	1.1	6
177	High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1161-1172.	1.9	5
178	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. <i>Cancers</i> , 2021, 13, 1807.	1.7	4
179	Epithelial argininosuccinate synthetase is dispensable for intestinal regeneration and tumorigenesis. <i>Cell Death and Disease</i> , 2021, 12, 897.	2.7	4
180	Epithelium-derived Indian Hedgehog restricts stromal expression of ErbB family members that drive colonic tumor cell proliferation. <i>Oncogene</i> , 2021, 40, 1628-1643.	2.6	4

#	ARTICLE	IF	CITATIONS
181	Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma. <i>JCO Precision Oncology</i> , 2022, 6, e2000447.	1.5	4
182	Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours. <i>European Journal of Cancer</i> , 2022, 170, 196-208.	1.3	4
183	Small intestinal mucosa expression of putative chaperone fls485. <i>BMC Gastroenterology</i> , 2010, 10, 27.	0.8	3
184	Abstract B1-05: R2: Accessible web-based genomics analysis and visualization platform for biomedical researchers. , 2015, , .		3
185	Production of the bullous pemphigoid antigen 230 (BP230) by <i>Saccharomyces cerevisiae</i> and <i>Pichia pastoris</i> . <i>Protein Expression and Purification</i> , 2003, 29, 141-147.	0.6	2
186	Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology. <i>Journal of Adolescent and Young Adult Oncology</i> , 2011, 1, 118-123.	0.7	2
187	Abstract 5506: SOX11 acts as part of the MYCN-WEE1 regulatory protein complex implicated in neuroblastoma. , 2017, , .		1
188	Altered Gut Structure and Anti-Bacterial Defense in Adult Mice Treated with Antibiotics during Early Life. <i>Antibiotics</i> , 2022, 11, 267.	1.5	1
189	Comprehensive RNA dataset of tissue and plasma from patients with esophageal cancer or precursor lesions. <i>Scientific Data</i> , 2022, 9, 86.	2.4	1
190	The Construction of Genome-Based Transcriptional Units. <i>OMICS A Journal of Integrative Biology</i> , 2009, 13, 105-114.	1.0	0
191	EXTH-06. AÂCANCER DRUG-ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES. <i>Neuro-Oncology</i> , 2017, 19, vi74-vi74.	0.6	0
192	PS02.237: IDENTIFICATION OF THREE DISTINCT BIOLOGICAL SUBTYPES IN ESOPHAGEAL AND JUNCTIONAL ADENOCARCINOMA BY RNA SEQUENCING. <i>Ecological Management and Restoration</i> , 2018, 31, 189-189.	0.2	0
193	PCLN-05. A BIOBANK OF PATIENT-DERIVED MOLECULARLY CHARACTERIZED ORTHOTOPIC PEDIATRIC BRAIN TUMOR MODELS FOR PRECLINICAL RESEARCH. <i>Neuro-Oncology</i> , 2018, 20, i155-i155.	0.6	0
194	Abstract 1428: A CpG island methylator phenotype defines a clinically aggressive subgroup of posterior fossa ependymoma. , 2012, , .		0
195	Abstract 3804: Rare DNA variants are enriched at the BARD1 locus and likely influence neuroblastoma susceptibility.. , 2013, , .		0
196	Abstract B41: Whole genome sequencing identifies tumor evolution events in relapse neuroblastoma. , 2014, , .		0
197	Abstract LB-209: Neuroblastoma is biphasic with classical neuro-epithelial cells and chemoresistant mesenchymal cells controlled by PRRX1-NOTCH signaling. , 2015, , .		0
198	Abstract 2980: Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
199	Abstract PR08: Neuroblastoma is biphasic and includes classical neuroepithelial cells and chemoresistant mesenchymal cells. , 2016, , .		0
200	Abstract PR06: TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Cancer Research, 2016, 76, PR06-PR06.	0.4	0
201	Abstract B09: MCL-1 inhibition improves ABT199 efficacy for BCL-2-dependent neuroblastoma. , 2016, , .		0
202	Abstract 2453: Neuroblastoma is bi-phasic and includes classical neuro-epithelial cells and chemo-resistant mesenchymal cells. , 2016, , .		0
203	Abstract A26: High frequency of Cytosine to Adenine mutations in neuroblastoma correlates with genomic aberrations in 8-Oxo-Guanine repair pathway. , 2017, , .		0
204	Abstract 3876: Active enhancers delineate intra-tumor heterogeneity of developmental states in neuroblastoma. , 2017, , .		0